Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 05 September 2013
One of the biggest changes to food and drug law changes by the 2010 passage of the Patient Protection and Affordable Care Act (PPACA), better known by most as Obamacare, was its provisions for the creation of a "biosimilars" pathway under Section XII of the law. But now one of the most influential states in the US is moving to restrict their eventual use, conceding arguments made by innovative biopharmaceutical manufacturers that physicians should be able to restrict the substitution of biological drugs with biosimilar equivalents approved by the US Food and Drug Administration (FDA).
Previous efforts to create a pathway for biosimilars under the 2009 Biologics Price Competition and Innovation Act (BPCI) were ultimately combined into the PPACA, which established the 351(k) pathway for FDA to approve biosimilars much in the same way as generic pharmaceutical get approved via the 505(j) pathway.
The tradeoff is thus: Innovative biological products receive 12 years of market exclusivity for products, while subsequent biologics which reference the studies used to approve the former are then able to obtain approval more easily since they would require less data.
But as Regulatory Focus has explained before, the biggest issue of all may well be whether a biosimilar product is interchangeable with the original reference listed drug (RLD). Unlike chemical drugs, which can generally be closely-if not exactly-approximated and be found to be therapeutically equivalent based on bioequivalence and pharmacokinetic/pharmacodynamics data, biologics are altogether a great deal more complicated.
Since many are formed using complex biological processes (e.g. in bioreactors), generic manufacturers would find it nearly impossible to create an exact copy of the RLD's protein structure due to either a slightly different starting biological material, a different manufacturing process, and a variety of other factors that could affect uptake of the drug.
Thus, the major question faced by regulators will almost certainly be threefold:
While FDA has yet to approve any biosimilar products (though it has released numerous guidance documents and received several investigational new drug applications for eventual 351(k) filings), that hasn't stopped some state legislators from moving to pre-emptively ban the practice of substituting biosimilar drugs.
The latest of those bills is California's SB 598, which would prevent a biosimilar from being substituted in place of the RLD by a pharmacist unless FDA has specifically found the two products to be interchangeable. It would also allow a physician to prevent a pharmacist from substituting a biosimilar product for its biosimilar equivalent even if they are found to be interchangeable-a boon to innovative companies which could leverage the measure to stifle generic competition.
The bill has already seen overwhelming approval in the California Senate and Assembly, and now awaits Gov. Jerry Brown's signature.
"SB 598 is timely legislation that provides a balanced framework governing the use of biosimilars and gives doctors and patients more and better choices," said Joseph Panetta, president of BIOCOM, a California-based life sciences organization. "California policymakers recognize that biosimilars may be approved for the U.S. healthcare market as early as 2014 and without an update to state law patients will not have full access to them."
The bill, however, has received sharp rebukes from both FDA and the Generic Pharmaceutical Association (GPhA), who say it undermines confidence in biosimilar drugs as a whole by implying that non-interchangeable drugs are less safe or effective than the original RLD.
"Efforts to undermine trust in these products are worrisome and represent a disservice to patients who could benefit from these lower cost treatments," said FDA spokeswoman Lisa Kubaska to In-Pharma Technologistlast week. "It is important for everyone to approach these issues with an understanding of both FDA's expertise in this area and what the 2010 law requires for approval of biosimilar and interchangeable products."
Kubaska notes that the PPACA already set a "very high bar" for biosimilar approvals and expressly allowed for substitution.
In a statement released on 4 September 2013, GPhA noted its "disappointment" in the impending passage of the law.
"The bill would create unnecessary barriers between Californians and newer, lower-cost versions of biologic therapies, known as biosimilars, particularly interchangeable biosimilars," it wrote. "For the sake of California patients, the California budget, and California taxpayers, GPhA calls on Governor Brown to veto SB 598."
GPhA also argued the bill would increase costs for taxpayers, noting that the inability to substitute for lower-cost drugs would raise costs for CA's state Medicaid plan, known as CalPERS.
Tags: California, Biosimilars, Biologics
Regulatory Focus newsletters
All the biggest regulatory news and happenings.